Comparative Pharmacology
Head-to-head clinical analysis: BETAXON versus LOPRESSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXON versus LOPRESSOR.
BETAXON vs LOPRESSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors, predominantly in cardiac tissue.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
50 mg orally twice daily, titrate up to 100 mg twice daily as needed.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Terminal elimination half-life: 3-7 hours (mean 4.5 h); may be prolonged in hepatic impairment or elderly
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Renal: ~95% (primarily as metabolites, <5% unchanged); fecal: ~5%
Category C
Category C
Beta-Blocker
Beta-Blocker